Business Wire

Lineage Logistics Celebrates the Grand Opening of Savannah Fresh-Port Wentworth Facility

20.4.2023 20:30:00 EEST | Business Wire | Press release

Share

Lineage Logistics (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REITs and integrated solutions providers worldwide, today celebrated the grand opening of its newest facility in Port Wentworth, Georgia. Savannah Fresh-Port Wentworth is strategically located near the Port of Savannah, the largest single-terminal container facility of its kind in North America and the third busiest container gateway in the U.S.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005218/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lineage Logistics' Savannah Fresh-Port Wentworth facility is strategically located near the Port of Savannah and will allow Lineage to process up to 1.4 million pounds of produce per day. (Photo: Business Wire)

The 220,000-square-foot facility offers cross-docking services for products to enter and exit the facility on the same day if needed, reducing storage time, creating cost efficiencies, and ensuring consumers receive fresh produce faster. The facility has 23 inbound and outbound lanes that can process more than 40 trucks daily, moving up to 1.4 million pounds of produce per day.

“Today, the demand for port-centric temperature-controlled storage has never been greater and our Fresh solution offerings at Lineage have never been more robust. Savannah Fresh-Port Wentworth will allow us to expand our Fresh offering to new and existing customers and also provides the needed capacity to improve market conditions,” said Jim Henderson, Vice President of Global Sales and Business Development at Lineage. “The opening of this new facility is a critical step for Lineage as we continuously work to reimagine the world’s food supply chain. We are honored to further our long-standing partnership with Georgia Ports Authority and look forward to building our presence in the state of Georgia, an essential hub for trade and innovation.”

For the past two years, Lineage has worked closely with the Savannah Economic Development Authority, Georgia Ports Authority, and the city of Port Wentworth to construct the Savannah Fresh-Port Wentworth facility in addition to its port-adjacent facility on Tremont Road in Savannah. The Savannah Fresh-Port Wentworth project resulted in a $78 million investment alone that created 65 new jobs, bringing Lineage’s total economic investment in Chatham County to over $100 million. To date, Lineage’s footprint in Georgia spans over 3 million sq. ft.

Savannah Fresh-Port Wentworth was designed to address the overwhelming influx in imports of fresh produce to ports in the Mid-Atlantic that lack the space to keep up with the demand. With proximity to the Port of Savannah, the new facility will enable Lineage to deliver larger quantities of fresh produce more efficiently to serve customers across the Southeast.

“With increasing demand for fresh produce capacity in Savannah, this new, state of the art facility is a welcome addition,” said Griff Lynch, Executive Director of the Georgia Ports Authority. “Lineage Logistics’ suite of services, such as cold-retreatment and onsite CBP inspections, will save time, help prevent loss and, ultimately, bring fresh food to market faster.”

Leaders from Lineage, business partners from the state of Georgia, community leaders from the city of Port Wentworth, and leadership from Georgia Ports Authority attended the facility’s grand opening.

About Lineage Logistics

Lineage is one of the leading temperature-controlled industrial REITs and integrated solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage has industry-leading expertise in end-to-end logistical solutions, an unrivaled real estate network, and develops and deploys innovative technology. This helps increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, helps feed the world. In recognition of the Company’s leading innovations and sustainability initiatives, Lineage was listed as No. 3 in the 2022 CNBC Disruptor 50 list, named a Deloitte US Best Managed Company in 2022, the No. 1 Data Science company, and 23rd overall on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change the World list in 2020. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lineage Logistics
Christina Wiese
734-608-1855
cwiese@lineagelogistics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release

Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release

Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye